Regenerative medicine deals with the "process of replacing, engineering or regenerating human or animal cells, tissues or organs to restore or establish normal function".[1] This field holds the promise of engineering damaged tissues and organs by stimulating the body's own repair mechanisms to functionally heal previously irreparable tissues or organs.[2]

A colony of human embryonic stem cells

Regenerative medicine also includes the possibility of growing tissues and organs in the laboratory and implanting them when the body cannot heal itself. When the cell source for a regenerated organ is derived from the patient's own tissue or cells,[3] the challenge of organ transplant rejection via immunological mismatch is circumvented.[4][5][6] This approach could alleviate the problem of the shortage of organs available for donation.

Some of the biomedical approaches within the field of regenerative medicine may involve the use of stem cells.[7] Examples include the injection of stem cells or progenitor cells obtained through directed differentiation (cell therapies); the induction of regeneration by biologically active molecules administered alone or as a secretion by infused cells (immunomodulation therapy); and transplantation of in vitro grown organs and tissues (tissue engineering).[8][9]

History edit

The ancient Greeks postulated whether parts of the body could be regenerated in the 700s BC.[10] Skin grafting, invented in the late 19th century, can be thought of as the earliest major attempt to recreate bodily tissue to restore structure and function.[11] Advances in transplanting body parts in the 20th century further pushed the theory that body parts could regenerate and grow new cells. These advances led to tissue engineering, and from this field, the study of regenerative medicine expanded and began to take hold.[10] This began with cellular therapy, which led to the stem cell research that is widely being conducted today.[12]

The first cell therapies were intended to slow the aging process. This began in the 1930s with Paul Niehans, a Swiss doctor who was known to have treated famous historical figures such as Pope Pius XII, Charlie Chaplin, and king Ibn Saud of Saudi Arabia. Niehans would inject cells of young animals (usually lambs or calves) into his patients in an attempt to rejuvenate them.[13][14] In 1956, a more sophisticated process was created to treat leukemia by inserting bone marrow from a healthy person into a patient with leukemia. This process worked mostly due to both the donor and receiver in this case being identical twins. Nowadays, bone marrow can be taken from people who are similar enough to the patient who needs the cells to prevent rejection.[15]

The term "regenerative medicine" was first used in a 1992 article on hospital administration by Leland Kaiser. Kaiser's paper closes with a series of short paragraphs on future technologies that will impact hospitals. One paragraph had "Regenerative Medicine" as a bold print title and stated, "A new branch of medicine will develop that attempts to change the course of chronic disease and in many instances will regenerate tired and failing organ systems."[16][17]

The term was brought into the popular culture in 1999 by William A. Haseltine when he coined the term during a conference on Lake Como, to describe interventions that restore to normal function that which is damaged by disease, injured by trauma, or worn by time.[18] Haseltine was briefed on the project to isolate human embryonic stem cells and embryonic germ cells at Geron Corporation in collaboration with researchers at the University of Wisconsin–Madison and Johns Hopkins School of Medicine. He recognized that these cells' unique ability to differentiate into all the cell types of the human body (pluripotency) had the potential to develop into a new kind of regenerative therapy.[19][20] Explaining the new class of therapies that such cells could enable, he used the term "regenerative medicine" in the way that it is used today: "an approach to therapy that ... employs human genes, proteins and cells to re-grow, restore or provide mechanical replacements for tissues that have been injured by trauma, damaged by disease or worn by time" and "offers the prospect of curing diseases that cannot be treated effectively today, including those related to aging".[21][22]

Later, Haseltine would go on to explain that regenerative medicine acknowledges the reality that most people, regardless of which illness they have or which treatment they require, simply want to be restored to normal health. Designed to be applied broadly, the original definition includes cell and stem cell therapies, gene therapy, tissue engineering, genomic medicine, personalized medicine, biomechanical prosthetics, recombinant proteins, and antibody treatments. It also includes more familiar chemical pharmacopeia—in short, any intervention that restores a person to normal health. In addition to functioning as shorthand for a wide range of technologies and treatments, the term “regenerative medicine” is also patient friendly. It solves the problem that confusing or intimidating language discourages patients.

The term regenerative medicine is increasingly conflated with research on stem cell therapies. Some academic programs and departments retain the original broader definition while others use it to describe work on stem cell research.[23]

From 1995 to 1998 Michael D. West, PhD, organized and managed the research between Geron Corporation and its academic collaborators James Thomson at the University of Wisconsin–Madison and John Gearhart of Johns Hopkins University that led to the first isolation of human embryonic stem and human embryonic germ cells, respectively.[24]

In March 2000, Haseltine, Antony Atala, M.D., Michael D. West, Ph.D., and other leading researchers founded E-Biomed: The Journal of Regenerative Medicine.[25] The peer-reviewed journal facilitated discourse around regenerative medicine by publishing innovative research on stem cell therapies, gene therapies, tissue engineering, and biomechanical prosthetics. The Society for Regenerative Medicine, later renamed the Regenerative Medicine and Stem Cell Biology Society, served a similar purpose, creating a community of like-minded experts from around the world.[26]

In June 2008, at the Hospital Clínic de Barcelona, Professor Paolo Macchiarini and his team, of the University of Barcelona, performed the first tissue engineered trachea (wind pipe) transplantation. Adult stem cells were extracted from the patient's bone marrow, grown into a large population, and matured into cartilage cells, or chondrocytes, using an adaptive method originally devised for treating osteoarthritis. The team then seeded the newly grown chondrocytes, as well as epithelial cells, into a decellularised (free of donor cells) tracheal segment that was donated from a 51-year-old transplant donor who had died of cerebral hemorrhage. After four days of seeding, the graft was used to replace the patient's left main bronchus. After one month, a biopsy elicited local bleeding, indicating that the blood vessels had already grown back successfully.[27][28]

In 2009, the SENS Foundation was launched, with its stated aim as "the application of regenerative medicine – defined to include the repair of living cells and extracellular material in situ – to the diseases and disabilities of ageing".[29] In 2012, Professor Paolo Macchiarini and his team improved upon the 2008 implant by transplanting a laboratory-made trachea seeded with the patient's own cells.[30]

On September 12, 2014, surgeons at the Institute of Biomedical Research and Innovation Hospital in Kobe, Japan, transplanted a 1.3 by 3.0 millimeter sheet of retinal pigment epithelium cells, which were differentiated from iPS cells through directed differentiation, into an eye of an elderly woman, who suffers from age-related macular degeneration.[31]

In 2016, Paolo Macchiarini was fired from Karolinska University in Sweden due to falsified test results and lies.[32] The TV-show Experimenten aired on Swedish Television and detailed all the lies and falsified results.[33]

Research edit

Widespread interest and funding for research on regenerative medicine has prompted institutions in the United States and around the world to establish departments and research institutes that specialize in regenerative medicine including: The Department of Rehabilitation and Regenerative Medicine at Columbia University, the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University, the Center for Regenerative and Nanomedicine at Northwestern University, the Wake Forest Institute for Regenerative Medicine, and the British Heart Foundation Centers of Regenerative Medicine at the University of Oxford.[34][35][36][37] In China, institutes dedicated to regenerative medicine are run by the Chinese Academy of Sciences, Tsinghua University, and the Chinese University of Hong Kong, among others.[38][39][40]

In dentistry edit

 
A diagram of a human tooth. Stem cells are located in the pulp in the center.[41]

Regenerative medicine has been studied by dentists to find ways that damaged teeth can be repaired and restored to obtain natural structure and function.[42] Dental tissues are often damaged due to tooth decay, and are often deemed to be irreplaceable except by synthetic or metal dental fillings or crowns, which requires further damage to be done to the teeth by drilling into them to prevent the loss of an entire tooth.

Researchers from King's College London have created a drug called Tideglusib that claims to have the ability to regrow dentin, the second layer of the tooth beneath the enamel which encases and protects the pulp (often referred to as the nerve).[43]

Animal studies conducted on mice in Japan in 2007 show great possibilities in regenerating an entire tooth. Some mice had a tooth extracted and the cells from bioengineered tooth germs were implanted into them and allowed to grow. The result were perfectly functioning and healthy teeth, complete with all three layers, as well as roots. These teeth also had the necessary ligaments to stay rooted in its socket and allow for natural shifting. They contrast with traditional dental implants, which are restricted to one spot as they are drilled into the jawbone.[44][45]

A person's baby teeth are known to contain stem cells that can be used for regeneration of the dental pulp after a root canal treatment or injury. These cells can also be used to repair damage from periodontitis, an advanced form of gum disease that causes bone loss and severe gum recession. Research is still being done to see if these stem cells are viable enough to grow into completely new teeth. Some parents even opt to keep their children's baby teeth in special storage with the thought that, when older, the children could use the stem cells within them to treat a condition.[46][47]

Extracellular matrix edit

Extracellular matrix materials are commercially available and are used in reconstructive surgery, treatment of chronic wounds, and some orthopedic surgeries; as of January 2017 clinical studies were under way to use them in heart surgery to try to repair damaged heart tissue.[48][49]

The use of fish skin with its natural constituent of omega 3, has been developed by an Icelandic company Kereceis.[50] Omega 3 is a natural anti-inflammatory, and the fish skin material acts as a scaffold for cell regeneration.[51][52] In 2016 their product Omega3 Wound was approved by the FDA for the treatment of chronic wounds and burns.[51] In 2021 the FDA gave approval for Omega3 Surgibind to be used in surgical applications including plastic surgery.[53]

Cord blood edit

Cord blood (umbilical cord blood) is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders such as cancer. Cord Blood can be used to treat over 80 different diseases.[54] "Over 8 million children around the world have their cord blood in private storage. Clinical trials around the world have used cord blood as therapy for cerebral palsy and other newborn brain disorders, autism, and for adults with stroke and other neurological conditions. At any time, over 100 clinical trials utilizing cord blood are recruiting participants." [55] There is growing interest from cell therapeutics companies in developing genetically modified allogeneic natural killer cells from umbilical cord blood as an alternative to CAR T cell therapies for rare diseases. Cord blood has also been studied as a treatment for diabetes.[56] Uses of cord blood beyond blood and immunological disorders is still rapidly evolving. Some research has been done in other areas.[57]

Along with cord blood, Wharton's jelly and the cord lining have been explored as sources for mesenchymal stem cells (MSC),[58] and as of 2015 had been studied in vitro, in animal models, and in early stage clinical trials for cardiovascular diseases,[59] as well as neurological deficits, liver diseases, immune system diseases, diabetes, lung injury, kidney injury, and leukemia.[60]

The American College of Obstetricians and Gynecologists recommends that Private umbilical cord blood banking may be considered when there is knowledge of a family member with a medical condition (malignant or genetic) who could potentially benefit from cord blood transplantation.[61]

The 2017 policy of the American Academy of Pediatrics, or AAP, states that "Cord blood is an excellent source of stem cells for hematopoietic stem cell transplantation in children with some fatal diseases. Cord blood transplantation offers another method of definitive therapy for infants, children, and adults with certain hematologic malignancies, hemoglobinopathies, severe forms of T-lymphocyte and other immunodeficiencies, and metabolic diseases." While private banking applications in the fields of Hematology/Oncology are more limited than those available for public cord blood banking, "new developments in early clinical trial research for regenerative purposes may affect cord blood banking in the future. Some examples of these trials of cord blood transplants are those for Alzheimer disease, autism spectrum disorder, diabetes, cerebral palsy, hypoxic ischemic encephalopathy, systemic lupus erythematosus, and systemic sclerosis. Perhaps the most immediate challenge is that of educating medical personnel, parents, and the public about the increasing need and uses of cord blood banking."[62]

The American Medical Association states "Transplants of umbilical cord blood have been recommended or performed to treat a variety of conditions. Cord blood is also a potential source of stem and progenitor cells with possible therapeutic applications. Physicians who provide obstetrical care should be prepared to inform pregnant women of the various options regarding cord blood donation or storage and the potential uses of donated samples. Physicians who participate in collecting umbilical cord blood for storage should Discuss the option of private banking of umbilical cord blood when there is a family predisposition to a condition for which umbilical cord stem cells are therapeutically indicated and encourage women who wish to donate umbilical cord blood to donate to a public bank if one is available when there is low risk of predisposition to a condition for which umbilical cord blood cells are therapeutically indicated."[63].

See also edit

References edit

  1. ^ Mason, Chris; Dunnill, Peter (2008). "A brief definition of regenerative medicine". Regenerative Medicine. 3 (1): 1–5. doi:10.2217/17460751.3.1.1. ISSN 1746-0751. PMID 18154457.
  2. ^ "UM Leads in the Field of Regenerative Medicine: Moving from Treatments to Cures - Healthcanal.com". 8 May 2014.
  3. ^ Mahla RS (2016). "Stem cells application in regenerative medicine and disease threpeutics". International Journal of Cell Biology. 2016 (7): 1–24. doi:10.1155/2016/6940283. PMC 4969512. PMID 27516776.
  4. ^ "Regenerative Medicine. NIH Fact sheet" (PDF). September 2006. Archived from the original (PDF) on 2011-10-26. Retrieved 2010-08-16.
  5. ^ Mason C; Dunnill P (January 2008). "A brief definition of regenerative medicine". Regenerative Medicine. 3 (1): 1–5. doi:10.2217/17460751.3.1.1. PMID 18154457.
  6. ^ "Regenerative medicine glossary". Regenerative Medicine. 4 (4 Suppl): S1–88. July 2009. doi:10.2217/rme.09.s1. PMID 19604041.
  7. ^ Riazi AM; Kwon SY; Stanford WL (2009). "Stem Cell Sources for Regenerative Medicine". Stem Cells in Regenerative Medicine. Methods in Molecular Biology. Vol. 482. pp. 55–90. doi:10.1007/978-1-59745-060-7_5. ISBN 978-1-58829-797-6. PMID 19089350.
  8. ^ Stoick-Cooper CL; Moon RT; Weidinger G (June 2007). "Advances in signaling in vertebrate regeneration as a prelude to regenerative medicine". Genes & Development. 21 (11): 1292–315. doi:10.1101/gad.1540507. PMID 17545465.
  9. ^ Muneoka K; Allan CH; Yang X; Lee J; Han M (December 2008). "Mammalian regeneration and regenerative medicine". Birth Defects Research. Part C, Embryo Today. 84 (4): 265–80. doi:10.1002/bdrc.20137. PMID 19067422.
  10. ^ a b "What is Regenerative Medicine?". University of Nebraska Medical Center. University of Nebraska. Retrieved 27 June 2020.
  11. ^ Rahlf, Sidsel Hald (2009). "The Use of Skin Grafting for the Treatment of Burn Wounds in Denmark 1870-1960". Dansk Medicinhistorisk Arbog. 37: 99–116. PMID 20509454. Retrieved June 27, 2020.
  12. ^ Sampogna, Gianluca; Guraya, Salman Yousuf; Forgione, Atonello (September 2015). "Regenerative medicine: Historical roots and potential strategies in modern medicine". Journal of Microscopy and Ultrastructure. 3 (3): 101–107. doi:10.1016/j.jmau.2015.05.002. PMC 6014277. PMID 30023189.
  13. ^ "Dr. Paul Niehans, Swiss Surgeon, 89". The New York Times. September 4, 1971. Retrieved 27 June 2020. Dr. Paul Niehans was a former physician of Pope Paul XII, among others. A surgeon who performed more than 50,000 operations in 40 years, he developed his own rejuvenation treatment by injecting humans with the foetus of unborn lambs and other animals.
  14. ^ Milton, Joyce (1998). Tramp: The Life of Charlie Chaplin. HarperCollins. ISBN 0060170522.
  15. ^ "1956: The First Successful Bone Marrow Transplantation". Home.cancerresearch. 7 December 2014. Archived from the original on 2 February 2020. Retrieved 26 July 2020.
  16. ^ Kaiser LR (1992). "The future of multihospital systems". Topics in Health Care Financing. 18 (4): 32–45. PMID 1631884.
  17. ^ Lysaght MJ; Crager J (July 2009). "Origins". Tissue Engineering. Part A. 15 (7): 1449–50. doi:10.1089/ten.tea.2007.0412. PMID 19327019.
  18. ^ https://www.nsf.gov/pubs/2004/nsf0450/ Viola, J., Lal, B., and Grad, O. The Emergence of Tissue Engineering as a Research Field. Arlington, VA: National Science Foundation, 2003.
  19. ^ Bailey, Ron (2005). Liberation Biology: The Scientific and Moral Case for the Biotech Revolution. Prometheus Books.
  20. ^ Alexander, Brian (January 2000). "Don't Die, Stay Pretty: The exploding science of superlongevity". Wired. Vol. 8, no. 1.
  21. ^ Haseltine, WA (6 July 2004). "The Emergence of Regenerative Medicine: A New Field and a New Society". E-biomed: The Journal of Regenerative Medicine. 2 (4): 17–23. doi:10.1089/152489001753309652.
  22. ^ Mao AS, Mooney DJ (Nov 2015). "Regenerative medicine: Current therapies and future directions". Proc Natl Acad Sci U S A. 112 (47): 14452–9. Bibcode:2015PNAS..11214452M. doi:10.1073/pnas.1508520112. PMC 4664309. PMID 26598661.
  23. ^ Sampogna, Gianluca; Guraya, Salman Yousuf; Forgione, Antonello (2015-09-01). "Regenerative medicine: Historical roots and potential strategies in modern medicine". Journal of Microscopy and Ultrastructure. 3 (3): 101–107. doi:10.1016/j.jmau.2015.05.002. ISSN 2213-879X. PMC 6014277. PMID 30023189.
  24. ^ "Bloomberg Longevity Economy Conference 2013 Panelist Bio". Archived from the original on 2013-08-03.
  25. ^ "E-Biomed: The Journal of Regenerative Medicine". E-Biomed. ISSN 1524-8909. Retrieved 2020-02-25.
  26. ^ Haseltine, William A (2011-07-01). "Interview: Commercial translation of cell-based therapies and regenerative medicine: learning by experience". Regenerative Medicine. 6 (4): 431–435. doi:10.2217/rme.11.40. ISSN 1746-0751. PMID 21749201.
  27. ^ "Tissue-Engineered Trachea Transplant Is Adult Stem Cell Breakthrough". Science 2.0. 2008-11-19. Retrieved 2010-03-19.
  28. ^ "Regenerative Medicine Success Story: A Tissue-Engineered Trachea". Mirm.pitt.edu. Archived from the original on 2010-06-12. Retrieved 2010-03-19.
  29. ^ "Sens Foundation". sens.org. 2009-01-03. Retrieved 2012-02-23.
  30. ^ Fountain, Henry (2012-01-12). "Surgeons Implant Synthetic Trachea In Baltimore Man". The New York Times. Retrieved 2012-02-23.
  31. ^ Cyranoski, David (12 September 2014). "Japanese woman is first recipient of next-generation stem cells". Nature. doi:10.1038/nature.2014.15915. ISSN 0028-0836. S2CID 86969754.
  32. ^ Oltermann, Philip (2016-03-24). "'Superstar doctor' fired from Swedish institute over research 'lies'". The Guardian. ISSN 0261-3077. Retrieved 2017-10-13.
  33. ^ Sweden, Sveriges Television AB, Stockholm. "Experimenten". svt.se (in Swedish). Retrieved 2017-10-13.{{cite web}}: CS1 maint: multiple names: authors list (link)
  34. ^ "Research". Institute for Stem Cell Biologyand Regenerative Medicine. Retrieved 2020-02-25.
  35. ^ "CRN Origins and Mission | Center for Regenerative Nanomedicine, Northwestern University". crn.northwestern.edu. Retrieved 2020-02-25.
  36. ^ "Wake Forest Institute for Regenerative Medicine (WFIRM)". Wake Forest School of Medicine. Retrieved 2020-02-25.
  37. ^ "Centres of Regenerative Medicine". www.bhf.org.uk. Retrieved 2020-02-25.
  38. ^ "Guangzhou Institute of Biomedicine and Health,Chinese Academy of Sciences". english.gibh.cas.cn. Retrieved 2020-02-25.
  39. ^ "Institute for Stem Cell Biology and Regenerative Medicine - School of Pharmaceutical Sciences Tsinghua University". www.sps.tsinghua.edu.cn. Archived from the original on 2016-10-04. Retrieved 2020-02-25.
  40. ^ administrator. "Home". Institute for Tissue Engineering and Regenerative Medicine. Retrieved 2020-02-25.
  41. ^ Lan, Xiaoyan; Sun, Zhengwu; Chu, Chengyan; Boltze, Johannes; Li, Shen (2 August 2019). "Dental Pulp Stem Cells: An Attractive Alternative for Cell Therapy in Ischemic Stroke". Frontiers in Neurology. 10: 824. doi:10.3389/fneur.2019.00824. PMC 6689980. PMID 31428038. S2CID 199022265.
  42. ^ Steindorff, Marina M.; Lehl, Helena; Winkel, Andreas; Stiesch, Meike (February 2014). "Innovative approaches to regenerate teeth by tissue engineering". Archives of Oral Biology. 59 (2): 158–66. doi:10.1016/j.archoralbio.2013.11.005. PMID 24370187. Retrieved 27 June 2020.
  43. ^ King's College London (March 10, 2020). "Teeth That Repair Themselves – Study Finds Success With Natural Tooth Repair Method". SciTech Daily. Retrieved 27 June 2020.
  44. ^ "Japanese scientists grow teeth from single cells". Reuters. February 20, 2007. Retrieved 27 June 2020.
  45. ^ Normile, Dennis (August 3, 2009). "Researchers Grow New Teeth in Mice". Science.
  46. ^ Childs, Dan (April 13, 2009). "Could Baby Teeth Stem Cells Save Your Child?". ABC News. Retrieved 27 June 2020.
  47. ^ Ratan-NM, M. Pharm (April 30, 2020). "Repairing Teeth using Stem Cells". News Medical Life Sciences. Retrieved 27 June 2020.
  48. ^ Saldin, LT; Cramer, MC; Velankar, SS; White, LJ; Badylak, SF (February 2017). "Extracellular matrix hydrogels from decellularized tissues: Structure and function". Acta Biomaterialia. 49: 1–15. doi:10.1016/j.actbio.2016.11.068. PMC 5253110. PMID 27915024.
  49. ^ Swinehart, IT; Badylak, SF (March 2016). "Extracellular matrix bioscaffolds in tissue remodeling and morphogenesis". Developmental Dynamics. 245 (3): 351–60. doi:10.1002/dvdy.24379. PMC 4755921. PMID 26699796.
  50. ^ Hannan, Daniel (October 25, 2020). "Taking back control of fishing could be an enormous growth opportunity for Britain". The Daily Telegraph.
  51. ^ a b "Fish Skin for Human Wounds: Iceland's Pioneering Treatment". Bloomberg Businessweek. 27 June 2017.
  52. ^ "Alaska's seafood industry by the numbers, plus fish skin's medical applications and antibiotics in Chilean salmon". Anchorage Daily News.
  53. ^ "FDA Approves Kerecis' Implantable Fish-Skin Product". Iceland Monitor.
  54. ^ "Standard Diseases Treated by Cord Blood Transplant". The Parent's Guide To Cord Blood. March 13, 2023.
  55. ^ "Cord Blood FAQs". The Parent's Guide To Cord Blood. March 13, 2023.
  56. ^ Haller M J; et al. (2008). "Autologous umbilical cord blood infusion for type 1 diabetes". Exp. Hematol. 36 (6): 710–15. doi:10.1016/j.exphem.2008.01.009. PMC 2444031. PMID 18358588.
  57. ^ Walther, Mary Margaret (2009). "Chapter 39. Cord Blood Hematopoietic Cell Transplantation". In Appelbaum, Frederick R.; Forman, Stephen J.; Negrin, Robert S.; Blume, Karl G. (eds.). Thomas' hematopoietic cell transplantation stem cell transplantation (4th ed.). Oxford: Wiley-Blackwell. ISBN 9781444303537.
  58. ^ Caseiro, AR; Pereira, T; Ivanova, G; Luís, AL; Maurício, AC (2016). "Neuromuscular Regeneration: Perspective on the Application of Mesenchymal Stem Cells and Their Secretion Products". Stem Cells International. 2016: 9756973. doi:10.1155/2016/9756973. PMC 4736584. PMID 26880998.
  59. ^ Roura S, Pujal JM, Gálvez-Montón C, Bayes-Genis A (2015). "Impact of umbilical cord blood-derived mesenchymal stem cells on cardiovascular research". BioMed Research International. 2015: 975302. doi:10.1155/2015/975302. PMC 4377460. PMID 25861654.
  60. ^ Li, T; Xia, M; Gao, Y; Chen, Y; Xu, Y (2015). "Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy". Expert Opinion on Biological Therapy. 15 (9): 1293–306. doi:10.1517/14712598.2015.1051528. PMID 26067213. S2CID 25619787.
  61. ^ "ACOG Committee Opinion Umbilical Cord Blood Banking". The American College of Obstetricians and Gynecologists. March 12, 2023.
  62. ^ "American Academy of Pediatrics Policy Statement, Cord Blood Banking for Potential Future Transplantation". American Academy of Pediatrics. March 12, 2023.
  63. ^ "AMA Code of Medical Ethics, Umbilical Cord Blood Banking". The American Medical Association. March 12, 2023.
  64. ^ Hsueh, Ming-Feng; Önnerfjord, Patrik; Bolognesi, Michael P.; Easley, Mark E.; Kraus, Virginia B. (October 2019). "Analysis of "old" proteins unmasks dynamic gradient of cartilage turnover in human limbs". Science Advances. 5 (10): eaax3203. Bibcode:2019SciA....5R3203H. doi:10.1126/sciadv.aax3203. ISSN 2375-2548. PMC 6785252. PMID 31633025.
  65. ^ "Humans Have Salamander-Like Ability to Regrow Cartilage in Joints". Duke Health. October 8, 2019.

Further reading edit

Non-technical further reading edit

Technical further reading edit